Sub menu

 

 

Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease

We have adopted this International Scientific Guideline - EMA/CHMP/330418/2012 rev. 2.

Last updated

About this guideline

Overseas effective date:  2 July 2012

Replaces: CPMP/EWP/563/95 Rev 1. Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease (Adopted by TGA 25 February 2009)

Note: To be read in conjunction with the Questions and answers on additional clarification for inclusion criteria in the “Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease” rev. 2 (EMA/351466/2012).

Categories: Clinical efficacy and safety | Nervous system

TGA annotations: Nil

  • Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
  • All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

For more information see International scientific guidelines adopted in Australia.

Product types